Search This Blog

Sunday, June 23, 2024

Fractyl Preclinical Data on Weight Maintenance, Body Composition from Single-Administration GLP-1

Single administration of Rejuva reduced fat mass and improved glycemia in the well-validated diet-induced obesity (DIO) mouse model

Rejuva also prevented weight and glycemic rebound after semaglutide withdrawal

Data provide first demonstration that Rejuva treatment has potential to mimic natural release of GLP-1 from pancreas

https://www.globenewswire.com/news-release/2024/06/23/2902704/0/en/Fractyl-Health-Presents-New-Preclinical-Data-on-Sustained-Weight-Maintenance-and-Improved-Body-Composition-from-its-Rejuva-Single-Administration-GLP-1-Pancreatic-Gene-Therapy-in-Pr.html

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.